MeCP2 is a potential pharmacological protein target associated with RTT (caused by defective MeCP2 activity) and MDS (caused by excess of MeCP2 activity), two neurological disorders with similar phenotypic features. Here, MECP2 is linked to myelodysplastic syndrome.